-
Summary of the highlights of the pharmaceutical equipment market in 2021: the proportion of biopharmaceutical products has increased rapidly
Time of Update: 2021-12-30
Chutian Technology said in a survey report disclosed on November 29 that one of the highlights of this year's business is: the rapid increase in the proportion of products used in the field of biopharmaceuticals, which accounted for more than 40% of revenue and new orders .
-
A pharmaceutical company was fined over 30 million!
Time of Update: 2021-12-30
Under the continuous tightening of supervision, it is not uncommon for pharmaceutical companies to be punished and warned by the provincial drug regulatory bureaus for the production and sales of counterfeit and inferior drugs .
-
Three local pharmaceutical companies move towards IPO, with a total fundraising of over 500 million U.S. dollars
Time of Update: 2021-12-30
According to the fixed increase draft, Northland's fixed increase financing will be used for drug research and development projects, bioengineering new drug industrialization projects and supplementary working capital, using the raised funds of 82.
-
The indications for first-line treatment of Iris vometinib mesylate tablets are planned to be included in the priority review
Time of Update: 2021-12-30
On December 8, the latest announcement on the CDE official website showed that Iris vometinib mesylate tablets are planned to be included in the priority review and are intended for use with epidermal growth factor receptor (EGFR) exon 19 deletion mutations (19DEL) or First-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with exon 21 replacement mutation (21L858R) .
-
The State Food and Drug Administration released the 49th batch of generic drug reference preparation catalog
Time of Update: 2021-12-30
On December 8, the State Food and Drug Administration issued an announcement stating that the 49th batch of generic drug reference preparations catalogue was now released after the review and determination of the Expert Committee on the Quality and Efficacy Consistency Evaluation of Generic Drugs of the State Drug Administration .
-
Daiichi Sankyo/AstraZeneca TROP-2 ADC releases latest data on triple-negative breast cancer cohort
Time of Update: 2021-12-30
On December 7, Daiichi Sankyo and AstraZeneca announced the TROP2 targeted antibody drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062a) in the phase 1 trial of TROPION-PanTumor01 to treat triple-negative breast cancer (TNBC) latest data .
-
More than 100 listed medical device companies disclosed the third quarter report of 2021: 12 revenue exceeded 5 billion yuan
Time of Update: 2021-12-30
Specifically, Mindray Medical's revenue and net profit in the first three quarters of 2021 achieved rapid growth compared with the same period in 2020, achieving operating income of 19.
-
Why doesn't the negotiation of medical insurance drugs directly show the low price?
Time of Update: 2021-12-30
On the one hand, for drugs that are eligible for negotiation, the medical insurance department organizes relevant companies to submit calculation data according to a unified template, which mainly includes: basic drug information, relevant safety, effectiveness, and economic information, intended prices, and corresponding evidence materials .
-
Hutchison Medical's introduction of anti-tumor drug tazemetostat tablets for more than 300 million US dollars applies for clinical application in China
Time of Update: 2021-12-30
Screenshot source: CDE official websitePublic information shows that tazemetostat is a "first-in-class" EZH2 methyltransferase inhibitor developed by Epizyme.
In addition, tazemetostat is also being developed for the treatment of diffuse large B-cell lymphoma, prostate cancer and ovarian cancer .
-
In the future, the development of my country's pharmaceutical industry will present three new trends
Time of Update: 2021-12-30
In recent years, as digitalization and intelligence have gradually become emerging forces in the transformation and upgrading of China's medical system, its integration and innovation with the pharmaceutical industry has also begun to become a new industry trend .
-
Digital innovation sweeps the Chinese medicine industry, opening the journey of "intelligent manufacturing"
Time of Update: 2021-12-30
With the development and application of new technologies such as the Internet of Everything, big data, and artificial intelligence, digital innovation is also a tradition The Chinese medicine industry has brought more room for imagination .
-
What is the problem of the recall of glass particles found in some of the new crown drug bottles in the United States?
Time of Update: 2021-12-30
Is the risk as big as we think?Recently, the FDA issued an announcement stating that some bottles of the new crown drug Remdesivir in the United States were found to contain glass particles.
-
In order to accelerate innovation, local pharmaceutical companies still need to strengthen these aspects
Time of Update: 2021-12-30
However, it is worth noting that the industry believes that in addition to continuing to accelerate the development of domestic innovative drugs in the future; in terms of R&D management, pharmaceutical companies should also play the role of R&D managers to improve R&D capabilities, including basic research and targets.
-
Frequent new drug transactions, highlighting the continuous improvement of the innovative strength of local pharmaceutical companies
Time of Update: 2021-12-30
Among them, the new drug authorization cooperation between Chinese companies is very active, such as Jichuan Pharmaceutical and Tianjing Biological, Hengrui Pharmaceuticals and CStone Pharmaceuticals, Geli and Corning Jereh, CSPC and Connoa Biologicals, etc.
-
AI pharmacy has become an upsurge, and domestic and foreign pharmaceutical companies are vying for layout
Time of Update: 2021-12-30
. It is worth mentioning that, as pharmaceutical companies continue to increase their weight in AI pharmacy, some companies have made substantial breakthroughs in the research and development of new drugs .
-
Due to the increase in the price of raw materials, the price of this medicine has risen to 860 yuan
Time of Update: 2021-12-30
Recently, it has been reported that Beijing Tongrentang issued a price adjustment notice, raising the selling price of Angong Niuhuang Pills (3g*pills/box) from 780 yuan to 860 yuan, an increase of about 10%.
-
Centralized procurement of Chinese patent medicines is raging, and the industry: a wave of price cuts is inevitable
Time of Update: 2021-12-30
However, the recent developments of the 19-province alliance led by Hubei Province on the centralized procurement of Chinese patent medicines have attracted the attention of the industry.
The analysis believes that the plummet of Fusen Pharmaceutical may be related to the centralized procurement of Chinese patent medicines led by Hubei Province.
-
Hengrui Medicine and Iktos of France reached a strategic cooperation on AI new drug R&D platform
Time of Update: 2021-12-30
According to the agreement, Hengrui will use Iktos' AI-based de novo drug design software Makya™ to accelerate the discovery of small molecule drugs and the optimization of lead compounds .
-
Prevent new coronary pneumonia!
Time of Update: 2021-12-30
Author: Shi BeiOn December 8, AstraZeneca announced that the FDA had approved an emergency use authorization application for its long-acting antibody cocktail therapy Evusheld (tixagevimab+cilgavimab) for the prevention of SARS-CoV-2 before exposure .
-
Merck halts two clinical trials of anti-AIDS drug islatravir
Time of Update: 2021-12-30
This decision is based on the recommendation of the external data monitoring committee (eDMC) of islatravir pre-exposure prevention (PrEP) that Merck suspends the recruitment of IMPOWER 22 and IMPOWER 24 clinical trials in order to facilitate the company’s evaluation of these studies.
